Addressing bottlenecks in immuno-oncology therapies 

Within our drug discovery world, unless we have contact with clinical settings, it is easy to lose sight that our expertise, time, laboratory instruments, software, reagents, tools, workflows and procedures etc. are ultimately designed for the benefit of real-life patients. 

On 4 November 2021, 9AM PT; 12PM ET; 4PM GMT; 5PM CET, DDW will host a free webinar, supported by Sartorius. 

Deriving Context from Immunological Data with Advanced Flow Cytometry will be presented by Nina Senutovitch Ph.D, Senior Scientist, Product Development, Cell Analytics, Sartorius.  

Detailed characterisation during the course of T cell development has the potential to offer greater insights leading to improved therapeutics, such as bispecific antibodies, checkpoint inhibitors and CAR-T cells, in cancer immunotherapies. 

There is much interest in reversing or overcoming the state of T cell exhaustion, particularly in the production of CAR-T cells by including checkpoint inhibitor antibodies. 

The ability to monitor and quantify activation profiles, and to quantify memory T cell populations, allows for a greater understanding of how T cells react to certain stimuli which in turn can provide insight into how well drugs will be able to harness the power of the immune system. 

CAR-NK cells may allow for highly specific, enhanced killing of tumour cells.  A critical process in evaluating new NK cell-mediated therapeutics is the ability to quantify NK cell activation and tumour killing in order to provide insight into potential treatment efficacy.  

It is natural to be focused on protocols, procedures and large amounts of multiple source data taking place within the laboratory, losing sight of the repercussions of the work is all too easy.  Do not lose sight of why you are researching and generating data.  One needs to be able to accurately and simply, visualize these data and apply them to real life clinical settings. 

You may say: ‘easier said than done’.  There may be bottlenecks implementing numerous instruments, protocols, microplates, test tubes, data points, controls, cells, phenotypes, commercial cell types and software platforms, which can distance a laboratory scientist from the context of their immunological data.   

Efficient and powerful instrumentation plus analysis tools, to swiftly interpret and visualize complex data sets, are critical for furthering the development of target-specific therapies. 

One potential solution is the use of a single platform, such as advanced flow cytometry, that combines high-throughput sample acquisition and small sample volumes, with robust real-time data analysis software, to simultaneously probe immunophenotype and function of T cell subsets.  This enables greater insight into the dynamics of the immune cell function, such as the ability to activate effector T cell populations or induce the formation of memory T cell subsets.   

This forthcoming webinar, ‘Deriving Context from Immunological Data with Advanced Flow Cytometry’, from Nina Senutovitch Ph.D, will provide valuable details to those immunologists wishing to address bottlenecks in the development and application of immuno-oncology therapies. 

Register for free here. 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free